TITLE

Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration

AUTHOR(S)
Pijnenburg, Y. A. L.; Schoonenboom, S. N. M.; Mehta, P. D.; Mehta, S. P.; Mulder, C.; Veerhuis, R.; Blankenstein, M. A.; Scheltens, P.
PUB. DATE
July 2007
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jul2007, Vol. 78 Issue 7, p735
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The role of amyloid metabolism in the pathophysiology of frontotemporal lobar degeneration (FTLD) has yet to be elucidated. We compared CSF levels of amyloid beta 1-40 (Aβ40) and amyloid beta 1-42 (Aβ42) in patients with FTLD (n = 21) versus patients with Alzheimer's disease (AD, n = 39) and in control subjects (n = 30). While in AD cases Aβ42 levels were lower and CSF Aβ40 levels equal to those in controls, a significant decrease in Aβ40 and increase in the CSF Aβ42/Aβ40 ratio was observed in FTLD compared with AD and control subjects. These findings favour a differential involvement of amyloid β peptides in FTLD compared with AD.
ACCESSION #
25595764

 

Related Articles

  • CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies. Bibl, M.; Mollenhauer, B.; Esselmann, H.; Lewczuk, P.; Trenkwalder, C.; Brechlin, P.; Rüther, E.; Kornhuber, J.; Otto, M.; Wiltfang, J. // Journal of Neural Transmission;Nov2006, Vol. 113 Issue 11, p1771 

    Differential diagnosis of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) is often crucial. CSF Tau protein and Amyloid-beta (Aβ) peptides have shown diagnostic value for the diagnosis of AD, but discrimination from DLB was poor. Herein, we investigate CSF of 18 patients...

  • Alzheimer's Disease.  // Current Medical Literature: Neurology;2006, Vol. 22 Issue 1, p27 

    Discusses several studies related to Alzheimer's disease. "Protection from Alzheimer's-like Disease in the Mouse by Genetic Ablation of Inducible Nitric Oxide Synthase," by C. Nathan, N. Calingasan, J. Nezezon et al; "Dementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin...

  • Probable NPH in patients with clinical AD: further support for the AD-NPH syndrome and CSF circulatory failure. Silverberg, G. D.; Mayo, M.; Fellmann, J.; Saul, T.; McGuire, D. // Cerebrospinal Fluid Research;2004 Supplement 1, Vol. 1, pS19 

    The article studies the incidence of elevated cerebrospinal fluid (CSF) pressure in patients with a clinical diagnosis of Alzheimer's disease (AD). The authors state that both AD and normal pressure hydrocephalus (NPH) are physiologically related to CSF circulatory failure. They report that if...

  • Therapeutic Potential of ? -Secretase Inhibitors and Modulators. Imbimbo, Bruno P. // Current Topics in Medicinal Chemistry;Jan2008, Vol. 8 Issue 1, p54 

    According to the �-amyloid (A�) hypothesis, compounds that inhibit ?-secretase, the pivotal enzyme that generates A�, are potential therapeutics for Alzheimer's disease (AD). Studies in both transgenic and non-transgenic animal models of AD have indicated that ?-secretase...

  • Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer’s disease. Johansson, Annica; Katzov, Hagit; Zetterberg, Henrik; Feuk, Lars; Johansson, Boo; Bogdanovic, Nenad; Andreasen, Niels; Lenhard, Boris; Brookes, Anthony J.; Pedersen, Nancy L.; Blennow, Kaj; Prince, Jonathan A. // Human Genetics;May2004, Vol. 114 Issue 6, p581 

    Recent studies have suggested that variants of CYP46A1, encoding cholesterol 24-hydroxylase (CYP46), confer risk for Alzheimer’s disease (AD), a prospect substantiated by evidence of genetic association from several quantitative traits related to AD pathology, including cerebrospinal...

  • Drug Library Screen to Identify Compounds that Decrease Secreted A� from a Human Cell Line. Chakrabarti, Enakshi; Smith, Jonathan D. // Current Alzheimer Research;Apr2005, Vol. 2 Issue 2, p255 

    In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid � peptide (A�) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16,...

  • Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors. Dickey, Chad A.; Eriksen, Jason; Kamal, Adeela; Burrows, Francis; Kasibhatla, Srinivas; Eckman, Christopher B.; Hutton, Mike; Petrucelli, Leonard // Current Alzheimer Research;Apr2005, Vol. 2 Issue 2, p231 

    Therapeutic development for Alzheimer's disease has largely focused on the removal of beta amyloid because of its suggested role in the primary agent in initiating the disease process. However, with the recent discovery of mutations that result as pathologic buildup of tau in the absence of...

  • Computer Simulations of Alzheimer's Amyloid β-Protein Folding and Assembly. Urbanc, Brigita; Cruz, Luis; Teplow, David B.; Stanley, H. Eugene // Current Alzheimer Research;Dec2006, Vol. 3 Issue 5, p493 

    Pathological folding and aggregation of the amyloid β-protein (Aβ) are widely perceived as central to understanding Alzheimer's disease (AD) at the molecular level. Experimental approaches to study Aβ self-assembly are limited, because most relevant aggregates are quasi-stable and...

  • Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimer's Disease. Golde, Todd E.; Dickson, Dennis; Hutton, Michael // Current Alzheimer Research;Dec2006, Vol. 3 Issue 5, p421 

    Advances in the understanding of Alzheimer's disease (AD) pathogenesis provide strong support for a modified version of the amyloid cascade hypothesis, which is now often referred to as the amyloid β protein (Aβ) cascade hypothesis. The basic tenant of this modified hypothesis is that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics